Related Experiment Videos

Macrolide-resistant Mycoplasma pneumoniae in children in Taiwan

Han-Meng Wu1, Kin-Sun Wong, Yhu-Chering Huang

  • 1Division of Pediatric Pulmonology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, 33305, Taiwan.

Insights

Macrolide-resistant Mycoplasma pneumoniae affects 12.3% of pediatric pneumonia cases in Taiwan. Resistant infections lead to longer hospital stays, highlighting the need for early diagnosis and appropriate treatment strategies.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Microbiology

Background:

  • Mycoplasma pneumoniae is a common cause of community-acquired pneumonia in children.
  • Macrolide resistance in M. pneumoniae is a growing global concern, potentially impacting treatment efficacy.
  • Understanding local resistance patterns is crucial for effective clinical management.

Purpose of the Study:

  • To determine the prevalence of macrolide-resistant (MR) M. pneumoniae in pediatric patients in Taiwan.
  • To compare the clinical outcomes of children with MR M. pneumoniae versus macrolide-susceptible (MS) M. pneumoniae infections.
  • To identify clinical predictors for differentiating MR from MS M. pneumoniae pneumonia.

Main Methods:

  • Retrospective review of medical records of pediatric patients diagnosed with mycoplasmal pneumonia.
  • Macrolide resistance detection for M. pneumoniae isolates.
  • Comparison of clinical courses, including hospital stay duration, between MR and MS M. pneumoniae groups.

Main Results:

  • The prevalence of macrolide resistance in M. pneumoniae was 12.3% among the studied pediatric population.
  • Patients with MR M. pneumoniae experienced significantly longer hospital stays (median 7 days) compared to those with MS M. pneumoniae (median 5 days; P=0.019).
  • Clinical, radiographic, and laboratory findings did not reliably differentiate between MR and MS M. pneumoniae pneumonia.

Conclusions:

  • Macrolide resistance in pediatric M. pneumoniae infections is a significant issue in Taiwan.
  • Early diagnosis of macrolide-resistant M. pneumoniae is essential for optimal patient management and to avoid unnecessary investigations.
  • Effective treatment strategies for macrolide-resistant M. pneumoniae require further investigation and development.

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...